Aventis “Contingency Plans” For Allegra Include Outlicensing
This article was originally published in The Tan Sheet
Executive Summary
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status